JP2004508304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508304A5 JP2004508304A5 JP2002523445A JP2002523445A JP2004508304A5 JP 2004508304 A5 JP2004508304 A5 JP 2004508304A5 JP 2002523445 A JP2002523445 A JP 2002523445A JP 2002523445 A JP2002523445 A JP 2002523445A JP 2004508304 A5 JP2004508304 A5 JP 2004508304A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- alkenyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heterocyclylamino Chemical group 0.000 claims description 142
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 4
- 101710085775 Melanocortin receptor 4 Proteins 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000000033 alkoxyamino group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005241 heteroarylamino group Chemical group 0.000 claims 3
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000004678 hydrides Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 106
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 55
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 48
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 34
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 29
- 229920002554 vinyl polymer Polymers 0.000 description 29
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- 125000004352 2-phenylcyclohexyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 3
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940117957 triethanolamine hydrochloride Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XOJSCPAYGRSALL-FTJBHMTQSA-N 4-[[N'-[(1S,2R)-2-aminocyclohexyl]-N-cyclohexylcarbamimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound N[C@H]1[C@H](CCCC1)N/C(=N\C1CCCCC1)/NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl XOJSCPAYGRSALL-FTJBHMTQSA-N 0.000 description 1
- JUAJTUBIUYDYSM-UHFFFAOYSA-N 4-[[N-(2-adamantyl)-C-(3,5-dimethylpiperazin-1-yl)carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1C(C2)CC3CC2CC1C3 JUAJTUBIUYDYSM-UHFFFAOYSA-N 0.000 description 1
- SCGJOCKIRPQRCE-UHFFFAOYSA-N 4-[[N-(3-aminocyclohexyl)-N'-cyclohexylcarbamimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound NC1CC(CCC1)N/C(=N\C1CCCCC1)/NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl SCGJOCKIRPQRCE-UHFFFAOYSA-N 0.000 description 1
- ULUAKWCUUHPYFB-UHFFFAOYSA-N 4-[[N-(4-tert-butylcyclohexyl)-C-(3,5-dimethylpiperazin-1-yl)carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1CCC(C(C)(C)C)CC1 ULUAKWCUUHPYFB-UHFFFAOYSA-N 0.000 description 1
- USQKRZFURYWKLE-NRFANRHFSA-N 4-[[N-cyclooctyl-C-[(3S)-3-methylpiperazin-1-yl]carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C[C@H]1CN(CCN1)C(NC1=CC=C(C=C1)C(=O)NCCC1=C(Cl)C=C(Cl)C=C1)=N/C1CCCCCCC1 USQKRZFURYWKLE-NRFANRHFSA-N 0.000 description 1
- GXFNBCKBVWMOEW-VTYYSHTASA-N 4-[[n-(2-adamantyl)-c-[(3s)-3-methylpiperazin-1-yl]carbonimidoyl]amino]-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1C(C2)CC3CC2CC1C3 GXFNBCKBVWMOEW-VTYYSHTASA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UOHUTMGUEZCFRD-ULJHMMPZSA-N C1(NCCC1)\C=C(/N1CCNCC1)\NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCC1)\C=C(/N1CCNCC1)\NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UOHUTMGUEZCFRD-ULJHMMPZSA-N 0.000 description 1
- KNLMHWSCNOCXCX-UHFFFAOYSA-N C1(NCCCC1)C=C(/N(CC1=CC=CC=C1)CC=1NC=CN1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C1(NCCCC1)C=C(/N(CC1=CC=CC=C1)CC=1NC=CN1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 KNLMHWSCNOCXCX-UHFFFAOYSA-N 0.000 description 1
- RLUSOBKCYXAKSI-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CC(NCC1)=O)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CC(NCC1)=O)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl RLUSOBKCYXAKSI-UHFFFAOYSA-N 0.000 description 1
- HSRXIQJMZZNUGP-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CC(NCC1)C1=CC=CC=C1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CC(NCC1)C1=CC=CC=C1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl HSRXIQJMZZNUGP-UHFFFAOYSA-N 0.000 description 1
- DFMVFAKJGQHCEJ-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCN(CC1)C(=O)C=1OC=CC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCN(CC1)C(=O)C=1OC=CC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl DFMVFAKJGQHCEJ-UHFFFAOYSA-N 0.000 description 1
- PPKQTKUYUHCJEZ-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCN2C(NC(C2C1)=O)=N)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCN2C(NC(C2C1)=O)=N)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl PPKQTKUYUHCJEZ-UHFFFAOYSA-N 0.000 description 1
- BXBNCVUOVXOYHO-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl BXBNCVUOVXOYHO-UHFFFAOYSA-N 0.000 description 1
- DVDBOEOOKYNGTM-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCNCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCNCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl DVDBOEOOKYNGTM-UHFFFAOYSA-N 0.000 description 1
- IULIQGICROPJCC-BCJTWVECSA-N C1(NCCCC1)\C=C(/N(CC1=NC=CC=C1)CC1=CC=C(C=C1)F)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C1(NCCCC1)\C=C(/N(CC1=NC=CC=C1)CC1=CC=C(C=C1)F)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 IULIQGICROPJCC-BCJTWVECSA-N 0.000 description 1
- BHMPFZUBYVWAPX-UHFFFAOYSA-N C1(NCCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl BHMPFZUBYVWAPX-UHFFFAOYSA-N 0.000 description 1
- YRDKFDWQXPTILW-VEILYXNESA-N C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=C/N1C(C2)CCC2C1 Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=C/N1C(C2)CCC2C1 YRDKFDWQXPTILW-VEILYXNESA-N 0.000 description 1
- QKRNCGQHBUQTTM-BVFVYWQFSA-N C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 QKRNCGQHBUQTTM-BVFVYWQFSA-N 0.000 description 1
- YTEWFZCSYNSRIB-PBDKAQRYSA-N C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 YTEWFZCSYNSRIB-PBDKAQRYSA-N 0.000 description 1
- PDLCFUVLHASXLU-GEVKEYJPSA-N CC(C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C Chemical compound CC(C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C PDLCFUVLHASXLU-GEVKEYJPSA-N 0.000 description 1
- UZMWIDULSWTKKU-GYZAEMSSSA-N CC([C@]1(C[C@](C2)(C1(C)C)[H])[H])C2\N=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound CC([C@]1(C[C@](C2)(C1(C)C)[H])[H])C2\N=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-GYZAEMSSSA-N 0.000 description 1
- SSQVVXGMQPZZIA-IXCHTMLJSA-N CC1N(C[C@@H](NC1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound CC1N(C[C@@H](NC1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl SSQVVXGMQPZZIA-IXCHTMLJSA-N 0.000 description 1
- WSDHIRSASMFWEU-KEDRUTJZSA-N CCCC1CCCCC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CCCC1CCCCC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 WSDHIRSASMFWEU-KEDRUTJZSA-N 0.000 description 1
- VZBNSHBEXKFQKM-QAAXHWMCSA-N CCCC1CCCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CCCC1CCCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 VZBNSHBEXKFQKM-QAAXHWMCSA-N 0.000 description 1
- YXGMHUDCULSRLD-BUUPBASBSA-N CC[C@@H]1CCCC[C@H]1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CC[C@@H]1CCCC[C@H]1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 YXGMHUDCULSRLD-BUUPBASBSA-N 0.000 description 1
- NRDIONMYKFXPOB-TYZIXWKHSA-N CC[C@H]1CN(CCN1)/C(=C\C2CCCN2)/NC3=CC=C(C=C3)C(=O)NCCC4=C(C=C(C=C4)Cl)Cl Chemical compound CC[C@H]1CN(CCN1)/C(=C\C2CCCN2)/NC3=CC=C(C=C3)C(=O)NCCC4=C(C=C(C=C4)Cl)Cl NRDIONMYKFXPOB-TYZIXWKHSA-N 0.000 description 1
- WDRRADZEYLHWGM-AMVUTOCUSA-N CSCC[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound CSCC[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl WDRRADZEYLHWGM-AMVUTOCUSA-N 0.000 description 1
- WWDGBVKQPQLVTH-PRIXLJELSA-N C[C@@H]1CN(C[C@H](N1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@@H]1CN(C[C@H](N1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl WWDGBVKQPQLVTH-PRIXLJELSA-N 0.000 description 1
- UJRBSAPXIFZQQF-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NC=CCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NC=CCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UJRBSAPXIFZQQF-XGLRFROISA-N 0.000 description 1
- FCJYBMZFIWJUTP-XNUZUHMRSA-N C[C@H]1CN(CCN1)C(=C/C1NCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl FCJYBMZFIWJUTP-XNUZUHMRSA-N 0.000 description 1
- CUJGCHBVRHEMLP-QHELBMECSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C CUJGCHBVRHEMLP-QHELBMECSA-N 0.000 description 1
- WVQCRMBPVMMYDY-HSTJUUNISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC WVQCRMBPVMMYDY-HSTJUUNISA-N 0.000 description 1
- CKNUAQIXZOWAOT-YMXDCFFPSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC(=C(C=C1Cl)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC(=C(C=C1Cl)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC CKNUAQIXZOWAOT-YMXDCFFPSA-N 0.000 description 1
- AIJDCWJTBGVOOO-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl AIJDCWJTBGVOOO-XGLRFROISA-N 0.000 description 1
- UPEPYJQTDBEJGA-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)F)F Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)F)F UPEPYJQTDBEJGA-XGLRFROISA-N 0.000 description 1
- PEVPONZZSPLIDA-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)Cl PEVPONZZSPLIDA-JINQPTGOSA-N 0.000 description 1
- QBDMLZJQQAXSMG-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)F Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)F QBDMLZJQQAXSMG-JINQPTGOSA-N 0.000 description 1
- ZFRWVFYIBOKDJM-BWDMCYIDSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 ZFRWVFYIBOKDJM-BWDMCYIDSA-N 0.000 description 1
- PFCSIBOKLCGDEN-BWDMCYIDSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC=1NC2=CC=CC=C2C1 Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC=1NC2=CC=CC=C2C1 PFCSIBOKLCGDEN-BWDMCYIDSA-N 0.000 description 1
- MSYDXDWHPUPCBE-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl MSYDXDWHPUPCBE-JINQPTGOSA-N 0.000 description 1
- UGVPHENFPFFALD-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UGVPHENFPFFALD-JINQPTGOSA-N 0.000 description 1
- LTEUPPPIPSIGBJ-QHELBMECSA-N C[C@H]1CN(CCN1)C(=C/CC1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/CC1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl LTEUPPPIPSIGBJ-QHELBMECSA-N 0.000 description 1
- RKRFINYEGTYJDM-NRFANRHFSA-N C[C@H]1CN(CCN1)C(Nc1ccc(cc1)C(=O)NCCc1ccc(F)cc1)=NC1Cc2ccccc2C1 Chemical compound C[C@H]1CN(CCN1)C(Nc1ccc(cc1)C(=O)NCCc1ccc(F)cc1)=NC1Cc2ccccc2C1 RKRFINYEGTYJDM-NRFANRHFSA-N 0.000 description 1
- QRIHJXNPGSJRGW-JINQPTGOSA-N C[C@H]1CN(CCN1C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl QRIHJXNPGSJRGW-JINQPTGOSA-N 0.000 description 1
- STJJZRLULHHRKL-RRZWQVKKSA-N C[C@H]1CN(C[C@H](N1)C)C(=C/C1NCCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(C[C@H](N1)C)C(=C/C1NCCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl STJJZRLULHHRKL-RRZWQVKKSA-N 0.000 description 1
- HZLLUBHAFFUVRR-YSMPRRRNSA-N ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1)=CC=C1N\C(N1C2CC(NC2)C1)=C\C1NCCCC1 Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1)=CC=C1N\C(N1C2CC(NC2)C1)=C\C1NCCCC1 HZLLUBHAFFUVRR-YSMPRRRNSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UZMWIDULSWTKKU-FBLYZMNKSA-N N(/[C@@H]1[C@@H](C)[C@]2(C[C@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound N(/[C@@H]1[C@@H](C)[C@]2(C[C@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-FBLYZMNKSA-N 0.000 description 1
- UZMWIDULSWTKKU-LELJEFGFSA-N N(/[C@H]1[C@H](C)[C@@]2(C[C@@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound N(/[C@H]1[C@H](C)[C@@]2(C[C@@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-LELJEFGFSA-N 0.000 description 1
- CNYGJUDGEDSWTQ-QZHYJAGHSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-(3,5-dimethylpiperazin-1-yl)-N-[(1R,2R)-2-methylcycloheptyl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 CNYGJUDGEDSWTQ-QZHYJAGHSA-N 0.000 description 1
- VDCBAUXICMHAOR-VHKJGQLFSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-(3,5-dimethylpiperazin-1-yl)-N-[(1R,2R)-2-methylcyclohexyl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 VDCBAUXICMHAOR-VHKJGQLFSA-N 0.000 description 1
- JDALQHJLLLZLSL-IMSLXYDMSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-[(3S)-3-methylpiperazin-1-yl]-N-(4-phenylcyclohexyl)carbonimidoyl]amino]benzamide Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N/C1CCC(C=2C=CC=CC=2)CC1 JDALQHJLLLZLSL-IMSLXYDMSA-N 0.000 description 1
- AIOYHECSCZDWOP-NRMJFJNESA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-N-(3,3,5-trimethylcyclohexyl)carbonimidoyl]amino]benzamide Chemical compound C1C(C)(C)CC(C)CC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 AIOYHECSCZDWOP-NRMJFJNESA-N 0.000 description 1
- OSRNFISLLNLGLB-VIHQBZHPSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[N-(4-methylcyclohexyl)-C-[(3S)-3-methylpiperazin-1-yl]carbonimidoyl]amino]benzamide Chemical compound C1CC(C)CCC1\N=C(N1C[C@H](C)NCC1)\NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 OSRNFISLLNLGLB-VIHQBZHPSA-N 0.000 description 1
- HEELVTUFYFNRBT-QHCPKHFHSA-N N-[2-(4-methoxyphenyl)ethyl]-4-[[C-[(3S)-3-methylpiperazin-1-yl]-N-(2-propan-2-ylphenyl)carbonimidoyl]amino]benzamide Chemical compound C[C@H]1CN(CCN1)\C(=N\C1=C(C=CC=C1)C(C)C)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)OC HEELVTUFYFNRBT-QHCPKHFHSA-N 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- WGBOHERIFRJILR-CMAULLTDSA-N n-[2-(2,4-dichlorophenyl)ethyl]-4-[[n-(3-methylcyclohexyl)-c-[(3s)-3-methylpiperazin-1-yl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)CCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 WGBOHERIFRJILR-CMAULLTDSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23056500P | 2000-08-31 | 2000-08-31 | |
| US24557900P | 2000-11-06 | 2000-11-06 | |
| PCT/US2001/027206 WO2002018327A2 (en) | 2000-08-31 | 2001-08-31 | Guanidinobenzamides as mc4-r agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004508304A JP2004508304A (ja) | 2004-03-18 |
| JP2004508304A5 true JP2004508304A5 (enExample) | 2008-06-26 |
| JP4166567B2 JP4166567B2 (ja) | 2008-10-15 |
Family
ID=26924350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002523445A Expired - Fee Related JP4166567B2 (ja) | 2000-08-31 | 2001-08-31 | 新規グアニジノベンズアミド |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6638927B2 (enExample) |
| EP (1) | EP1409468B9 (enExample) |
| JP (1) | JP4166567B2 (enExample) |
| KR (1) | KR20030034163A (enExample) |
| CN (1) | CN1659156A (enExample) |
| AP (1) | AP2003002755A0 (enExample) |
| AT (1) | ATE414067T1 (enExample) |
| AU (2) | AU2001288604B2 (enExample) |
| BG (1) | BG107639A (enExample) |
| BR (1) | BR0113643A (enExample) |
| CA (1) | CA2420694C (enExample) |
| CZ (1) | CZ2003882A3 (enExample) |
| DE (1) | DE60136571D1 (enExample) |
| DZ (1) | DZ3415A1 (enExample) |
| EA (1) | EA200300323A1 (enExample) |
| ES (1) | ES2316467T3 (enExample) |
| HU (1) | HUP0302067A2 (enExample) |
| IL (1) | IL154604A0 (enExample) |
| MA (1) | MA26948A1 (enExample) |
| MX (1) | MXPA03001813A (enExample) |
| NO (1) | NO20030929L (enExample) |
| NZ (1) | NZ524897A (enExample) |
| PL (1) | PL360698A1 (enExample) |
| PT (1) | PT1409468E (enExample) |
| SI (1) | SI21267A (enExample) |
| SK (1) | SK3832003A3 (enExample) |
| WO (1) | WO2002018327A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1767525A1 (en) * | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| MXPA03011566A (es) | 2001-06-11 | 2004-10-28 | Xenoport Inc | Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida. |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| US20030207814A1 (en) * | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
| US20050124652A1 (en) * | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
| EP1487474A4 (en) * | 2002-02-25 | 2006-11-29 | Chiron Corp | INTRANASAL ADMINISTRATION OF MC4-R AGONISTS |
| DE60333937D1 (de) | 2002-05-23 | 2010-10-07 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
| US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| WO2004050610A2 (en) * | 2002-12-04 | 2004-06-17 | Gene Logic Inc. | Modulators of melanocortin receptor |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| KR20060018217A (ko) * | 2003-05-23 | 2006-02-28 | 카이론 코포레이션 | Ｍｃ4-ｒ 작용제로서 구아니디노-치환된 퀴나졸리논 화합물 |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| EP1661898A4 (en) | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | BICYCLIC PIPERAZINE COMPOUND AND ITS USE |
| EP1686996A4 (en) * | 2003-11-19 | 2008-11-12 | Novartis Vaccines & Diagnostic | CHINAZOLINONE COMPOUNDS WITH REDUCED BIOAC CUMULATION |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
| US7795448B2 (en) | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
| EP1811986B1 (en) | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| WO2007022964A2 (de) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| EP2348016B1 (en) | 2006-06-09 | 2016-02-17 | SynAct Pharma ApS | Phenyl pyrrole aminoguanidine derivatives |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| PT3773558T (pt) | 2019-05-10 | 2022-09-13 | Synact Pharma Aps | Tratamento combinado de doença artrítica |
| AU2022296767A1 (en) | 2021-06-21 | 2024-02-01 | Synact Pharma Aps | Phenyl pyrrole aminoguanidine salts and formulations |
| CN115850117B (zh) * | 2022-11-15 | 2024-06-04 | 黎明化工研究设计院有限责任公司 | 一种制备1,4-环己烷二异氰酸酯的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3177218A (en) * | 1962-01-17 | 1965-04-06 | Monsanto Chemicals | Methylene-bis(2-guanidino-4-methylquinazoline) |
| DE2623846A1 (de) * | 1976-05-28 | 1977-12-15 | Hoechst Ag | 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung |
| US4287341A (en) * | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| EP0059597B1 (en) * | 1981-02-27 | 1986-04-23 | Imperial Chemical Industries Plc | Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity |
| EP0067508B1 (en) * | 1981-05-18 | 1985-10-30 | Imperial Chemical Industries Plc | Amidine derivatives |
| US4921939A (en) * | 1985-03-19 | 1990-05-01 | Universite Claude Bernard -Lyon 1 | Sweetening agents |
| JPS6229566A (ja) | 1985-07-30 | 1987-02-07 | Taiyo Yakuhin Kogyo Kk | 新規グアニジノメチル安息香酸誘導体 |
| US4948891A (en) | 1988-05-24 | 1990-08-14 | Pfizer Inc. | Benzamide protease inhibitors |
| US4948901A (en) | 1988-05-24 | 1990-08-14 | Pfizer Inc. | Benzamide protease inhibitors |
| US4874864A (en) | 1988-05-24 | 1989-10-17 | Pfizer Inc. | Benzamide protease inhibitors |
| US5055479A (en) | 1988-06-16 | 1991-10-08 | Sankyo Company, Limited | Method of treating cachexia |
| GB8926512D0 (en) | 1989-11-23 | 1990-01-10 | Pfizer Ltd | Therapeutic agents |
| CA2032420A1 (en) * | 1989-12-22 | 1991-06-23 | Akira Okuyama | Guanidinobenzene derivatives |
| US5124328A (en) | 1990-10-11 | 1992-06-23 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| DK0690851T3 (da) | 1993-03-23 | 1999-11-08 | Astra Ab | Guanidin-derivater, som er anvendelige til behandling |
| US5807885A (en) | 1993-08-12 | 1998-09-15 | Astra Aktiebolag | Amidine derivatives with nitric oxide synthetase activities |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| US5599984A (en) | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| US5637439A (en) | 1994-11-07 | 1997-06-10 | Mitsubishi Paper Mills Ltd. | Photographic silver halide photosensitive material and method for developing the same |
| WO1996024580A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| PT891325E (pt) | 1996-03-29 | 2002-07-31 | Searle & Co | Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina |
| US5889025A (en) | 1996-05-06 | 1999-03-30 | Reddy's Research Foundation | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| US6127343A (en) | 1996-05-14 | 2000-10-03 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| ES2176776T3 (es) | 1996-08-23 | 2002-12-01 | Agouron Pharma | Ligandos del neuropeptido-y. |
| WO1998018786A1 (en) | 1996-10-31 | 1998-05-07 | Novo Nordisk A/S | Constrained somatostatin agonists and antagonists |
| DE69732244T2 (de) * | 1996-11-25 | 2006-06-29 | The Board Of Regents Of The University Of Nebraska, Lincoln | Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten |
| JP2001518069A (ja) | 1997-05-02 | 2001-10-09 | ドクター・レディーズ・リサーチ・ファウンデーション | 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物 |
| WO1999064002A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| DE19831710A1 (de) * | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| FR2784678B1 (fr) | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| US6297233B1 (en) * | 1999-02-09 | 2001-10-02 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| BR0012984A (pt) * | 1999-08-04 | 2002-07-16 | Millennium Pharm Inc | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| JP2003520850A (ja) | 2000-01-28 | 2003-07-08 | メラキュア セラピューティクス エービー | 新規なメラノコルチン受容体作動薬および拮抗薬 |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| EP1268449A4 (en) | 2000-03-23 | 2004-09-15 | Merck & Co Inc | SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS |
| EP1268000A4 (en) | 2000-03-23 | 2004-12-29 | Merck & Co Inc | SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS |
| GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| EP1767525A1 (en) * | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists |
| DE60333937D1 (de) | 2002-05-23 | 2010-10-07 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
-
2001
- 2001-08-21 DZ DZ013415A patent/DZ3415A1/fr active
- 2001-08-31 CN CN018177182A patent/CN1659156A/zh active Pending
- 2001-08-31 ES ES01968352T patent/ES2316467T3/es not_active Expired - Lifetime
- 2001-08-31 SI SI200120058A patent/SI21267A/sl not_active IP Right Cessation
- 2001-08-31 EA EA200300323A patent/EA200300323A1/ru unknown
- 2001-08-31 PL PL36069801A patent/PL360698A1/xx not_active Application Discontinuation
- 2001-08-31 AU AU2001288604A patent/AU2001288604B2/en not_active Ceased
- 2001-08-31 PT PT01968352T patent/PT1409468E/pt unknown
- 2001-08-31 SK SK383-2003A patent/SK3832003A3/sk unknown
- 2001-08-31 MX MXPA03001813A patent/MXPA03001813A/es active IP Right Grant
- 2001-08-31 US US09/945,384 patent/US6638927B2/en not_active Expired - Fee Related
- 2001-08-31 CZ CZ2003882A patent/CZ2003882A3/cs unknown
- 2001-08-31 AP APAP/P/2003/002755A patent/AP2003002755A0/en unknown
- 2001-08-31 IL IL15460401A patent/IL154604A0/xx unknown
- 2001-08-31 HU HU0302067A patent/HUP0302067A2/hu unknown
- 2001-08-31 AU AU8860401A patent/AU8860401A/xx active Pending
- 2001-08-31 JP JP2002523445A patent/JP4166567B2/ja not_active Expired - Fee Related
- 2001-08-31 AT AT01968352T patent/ATE414067T1/de not_active IP Right Cessation
- 2001-08-31 CA CA002420694A patent/CA2420694C/en not_active Expired - Fee Related
- 2001-08-31 NZ NZ524897A patent/NZ524897A/en unknown
- 2001-08-31 EP EP01968352A patent/EP1409468B9/en not_active Expired - Lifetime
- 2001-08-31 DE DE60136571T patent/DE60136571D1/de not_active Expired - Lifetime
- 2001-08-31 BR BR0113643-7A patent/BR0113643A/pt not_active IP Right Cessation
- 2001-08-31 KR KR10-2003-7003017A patent/KR20030034163A/ko not_active Withdrawn
- 2001-08-31 WO PCT/US2001/027206 patent/WO2002018327A2/en not_active Ceased
-
2003
- 2003-02-27 NO NO20030929A patent/NO20030929L/no not_active Application Discontinuation
- 2003-02-28 MA MA27062A patent/MA26948A1/fr unknown
- 2003-03-04 US US10/379,397 patent/US6995269B2/en not_active Expired - Fee Related
- 2003-03-18 BG BG107639A patent/BG107639A/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI104069B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(fenyyli- tai sykloalkyyli)-3-hydroksi-1-fenyylisulfonyyli-2-indoliinikarboksamidijohdannaisten valmistamiseksi | |
| JP4075064B2 (ja) | ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩 | |
| ES2258331T3 (es) | Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos. | |
| AU764216B2 (en) | Substituted benzimidazoles and their use as parp inhibitors | |
| TWI248435B (en) | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions | |
| JP2006504761A5 (enExample) | ||
| CA2436526A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| WO2006022442A1 (ja) | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 | |
| HRP20120069T1 (hr) | Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii | |
| JP2010505881A5 (enExample) | ||
| JP2007507529A (ja) | 複素環式アミドおよびスルホンアミド | |
| JP2007519695A5 (enExample) | ||
| JPH08508738A (ja) | ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体 | |
| JP2010501587A5 (enExample) | ||
| JP2004523490A5 (enExample) | ||
| RU2005111968A (ru) | Производные 4-пирролидинофенилбензилового эфира | |
| BG107639A (bg) | Гуанидинобензамиди като мс4-r агонисти | |
| JP2012507525A5 (enExample) | ||
| CA2618511A1 (en) | Novel benzothiazolone derivatives | |
| JP2013509376A5 (enExample) | ||
| RU2004135567A (ru) | Основные непептидные антагонисты брадикинина и их фармацевтические композиции | |
| RU2006113948A (ru) | Производные пиридина и их применение в качестве антагонистов уротензина ii | |
| US8492384B2 (en) | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | |
| JP2004525173A5 (enExample) | ||
| RU2007127864A (ru) | Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов |